Search

Search Constraints

You searched for: Author/Creator Shimoji, Masaki

Search Results

1. In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial. (December 2021)

3. Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer. (April 2021)

4. Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy‐Naive Isogenic Lung Cancer Lesions withEGFRMutation. Issue 10 (October 2016)

6. Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study. (December 2018)

7. Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro. (December 2018)

9. Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer. (October 2017)